Why GLP-1 medication is a prescription and not a purchase
Almost everyone who asks about this medicine has already read about it, and a good number have been offered it by an account on a phone with nobody asking what else they take in the morning. The legal position comes first here, so it goes first.
GLP-1 receptor agonists are classified as Group B poisons under the Poisons Act 1952. The Act sets out what that means: a Group B poison is dispensed against a prescription from a registered medical practitioner, a dentist or a veterinary surgeon. Reported alongside that classification is the consequence, that supplying these medicines outside those conditions is a criminal offence.
The same classification is why this article names no product. The Medicine Advertisements Board does not permit poisons in the First Schedule of the Act to be advertised to the public unless exempted. So the class gets named and nothing else does, which describes how the medicine is meant to move: through an examination rather than a feed. The guide to how clinics here are regulated sets out which law governs which part.
Does the number on the scale decide it?
Partly, and less than most people expect. The Ministry of Health and Malaysian Endocrine and Metabolic Society guideline on obesity sets pharmacotherapy at a body mass index of 30 or above, or 27.5 or above with comorbidities, and only as an adjunct to changes in diet, activity and behaviour. It is not indicated on its own.
The thresholds are Asian ones and sit lower than the figures people quote from overseas: 18.5 to 22.9 normal, 23.0 to 27.4 pre-obese, 27.5 to 32.4 obese class I, 32.5 to 37.4 class II, 37.5 or above class III. Waist circumference sits beside it, at 90 cm for men and 80 cm for women.
Then the guideline is candid about its own tool. BMI does not distinguish muscle from fat and says nothing about where fat sits, so visceral adiposity is the better parameter. Two people reach the same number for opposite reasons, which is where the assessment does work a calculator cannot.
The history that can stop it before it starts
The family thyroid question is not small talk, and it arrives early. At the weight management dose the prescribing information for this class carries a boxed warning about thyroid C-cell tumours seen in rodents, and the medicine is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma, with multiple endocrine neoplasia syndrome type 2, or who has reacted seriously to it before. The Malaysian guideline's drug table carries the same warnings.
Pregnancy is a contraindication, and the label goes further than the word suggests. Weight loss offers no benefit in pregnancy and may cause fetal harm, the medicine is stopped once a pregnancy is recognised, and discontinued at least two months before a planned one because of the long half-life. That is a conversation about the next two years.
The guideline table also warns on acute pancreatitis and gall bladder disease, on hypoglycaemia where the medicine is combined with insulin or an insulin secretagogue, on renal impairment below an eGFR of 15 ml per minute for one agent, and on transient worsening of retinopathy in type 2 diabetes where retinopathy is already present and control improves quickly. None of that is a complete list. It is a class summary from two documents, and whether any item applies to a particular person is decided from a full history in a consultation.
The question about your next anaesthetic
Malaysia's National Pharmaceutical Regulatory Agency has issued a safety alert on this class and anaesthesia, and patients rarely arrive knowing about it. These medicines slow the emptying of the stomach, part of how they work, so a stomach may still hold food at the moment everyone assumes it is empty. The alert states that this may raise the risk of aspiration and aspiration pneumonia during general anaesthesia or deep sedation.
The advice puts the work on the patient as much as the doctor: tell your doctors about any planned procedure requiring anaesthesia, and make the perioperative decision a shared one. That means the dentist offering sedation, the surgeon booking a day case, the endoscopy list.
So it becomes a question at the start, not a discovery later. Anything booked, anything likely this year. A strange thing to be asked at a weight appointment.
What happens next, and the rule for stopping
The guideline sets a review cadence and a stopping rule, and the stopping rule is the more interesting half. Face-to-face review is monthly for three months, then at least three-monthly. If more than 5% weight loss has not been achieved by three months, or there are significant safety or tolerability problems, the guideline says to stop and consider another approach.
A written instruction to stop is unusual in a field where most protocols describe only when to start. A medicine producing nothing still carries its side effect profile.
Loss at any speed brings a second conversation. What happens to skin after a significant loss has a limit no device changes, and it is better raised at the beginning than discovered in a mirror.
The version sold online is a different medicine
In January 2026 the Malaysian Obesity Society issued a public health warning about unregulated GLP-1 and GLP-1 with GIP compounds sold through online platforms, social media and other non-medical channels. Safe use, the society says, depends on proper patient selection, dose titration and monitoring, none of which exists inside that transaction.
Their warning lists what unsupervised use can produce: severe nausea and vomiting, dehydration, hypoglycaemia, pancreatitis or gall bladder disease, worsening of conditions the seller never asked about, and dangerous interactions with medicines nobody reviewed. Products sold this way may carry the wrong dose, contaminants, or a substance entirely different from the label.
Someone buying that way has not found a cheaper version of the same thing. They have bought an unknown.
The check that no examination can do
Everything above is answerable in a room, from a history, an examination and results. The question that decides most of what follows is not on that list.
It is what happens when the medicine stops. The guideline builds stopping into the plan from the start, with a review cadence and a rule for ending it, so that is a scheduled question rather than a failure. What the evidence shows about weight returning once the medicine stops is worth reading before the first prescription rather than after the last one.
A doctor who works through every item above and never asks it has done the safety checking and left the deciding question unasked. It is the slowest part of the appointment and it earns the time.
